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CHARACTERIZATION OF NOTCH1 AND PI3K-PTEN-AKT/mTOR PATHWAY 
INTERACTION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA 
 
Kyriante’ Savonn Henry, B.S. 
 
Advisory Professor: Faye M. Johnson, M.D., Ph.D. 
 
Head and neck squamous cell carcinoma (HNSCC) affects various mucosal sites 
of the upper aerodigestive tract, including the nasal and oral cavities, the nasopharynx, 
and the oropharynx. More than five hundred thousand new cases of HNSCC occurred in 
2011 alone, with 50,000 reported cases in the United States. This trend made HNSCC 
the seventh most common non-skin cancer worldwide (Ferlay et al., 2015). Although 
significant epidemiological and pathological advancements have been made, survival 
rates have not improved much over the last 40 years, leaving a mortality rate that remains 
at approximately 50%. An unbiased drug screen demonstrated that HNSCC cell lines 
bearing NOTCH1 inactivating mutations are sensitive to PI3K and dual PI3K/mTOR 
inhibitors, leading us to investigate the interaction of these pathways in HNSCC.  The 
NOTCH pathway plays key roles in cell proliferation, differentiation, and apoptosis. With 
inactivating mutations in 18% of 510 HNSCC patient samples, NOTCH1 is one of the 
most frequently altered genes in HNSCC (TCGA, Provisional). In 21 patients with 
HNSCC tumors, approximately 28 NOTCH1 mutations predicted tumor suppressive 
properties (Agrawal et al., 2011). The PI3K/mTOR pathway is a critical regulator of cell 
growth, proliferation, differentiation, and survival. It is the most frequently altered 
pathway in HNSCC, occurring in approximately 80% of HNSCC tumors (Iglesias-
Bartolome R, et al., 2013). Previous research suggests that NOTCH1 regulates PI3K-
 vii  
AKT and mTOR1 signaling in T-ALL cells by decreasing PTEN expression. In addition, 
blocking NOTCH1 activity has been shown to upregulate PTEN activity in T-ALL cells via 
Hes1 downregulation (Palomero T, et al., 2007). Unfortunately, the mechanism of 
communication between the two pathways is unknown in HNSCC. Understanding the 
interaction between the NOTCH1 and PI3K/AKT/mTOR signaling pathways presents 
them as essential targeting agents that may have a significant impact on modern 
therapeutic medicine. In this research, we sought to investigate whether the NOTCH1 
pathway regulates the activity of the PI3K-PTEN-AKT/mTOR pathway in HNSCC in vitro. 
The data of various experiments aimed at manipulating NOTCH1 activation and HES1 
expression suggests that the NOTCH1 pathway does not affect the PI3K-PTEN-
AKT/mTOR pathway in HNSCC. 
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CHAPTER 1: INTRODUCTION 
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1.1 Head and Neck Squamous Cell Carcinoma 
Head and neck squamous cell carcinoma (HNSCC) ranks among the most lethal, 
common non-skin types of cancer around the world. The disease affects ~600,000 
people around the world annually (Jemal et al., 2011). More than five hundred thousand 
new cases of HNSCC occurred in 2011 alone, with 50,000 reported cases in the United 
States (Agrawal et al., 2011). These trends make HNSCC the seventh most common 
non-skin cancer worldwide (Ferlay et al., 2015). HNSCC affects various mucosal sites of 
the upper aerodigestive tract, including the nasal cavity, the oral cavity, the larynx, and 
the pharynx. Figure 1 illustrates the regions of the upper aerodigestive tract that are 
affected by head and neck cancer. Tobacco use, alcohol consumption, and infection with 
high-risk types of human papillomavirus (HPV) are major risk factors for developing 
HNSCC (Stransky et al., 2011). In fact, the combination of tobacco and heavy alcohol 
consumption has a strong synergistic effect on worsening disease prognosis. The 5-year 
survival rate is only ~50% in head and neck cancer (Jemal et al., 2011; Kamangar et al., 
2006). Although previous research has made significant epidemiological and 
pathological advancements, survival rates have not improved much over the last 40 
years (Agrawal et al., 2011). Some treatment methods can result in various cosmetic 
deformities and impaired vital functions, such as difficulty breathing, swallowing, 
speaking, tasting, hearing, and smelling. Cetuximab, a monoclonal antibody targeting 
epidermal growth factor receptor (EGFR), is currently the only approved targeted therapy 
for treating head and neck cancer. However, only a subtle improvement has been 
detected in the overall survival of head and neck cancer patients (Baselga et al., 2005). 
A deeper understanding of this morbid malignancy’s pathogenesis and the role of 
recently identified genetic mutations is needed to develop more effective and targeted 
therapeutic approaches.     
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Figure 1: Anatomy of Head and Neck Squamous Cell Carcinoma.  
Head and neck squamous cell carcinoma affects various mucosal sites of the upper 
aerodigestive tract. This encompasses the nasal cavity, the oral cavity, the paranasal 
sinuses, the tongue, the salivary glands, the larynx, and the pharynx (including the 
nasopharynx, the oropharynx, and the hypopharynx). Permission obtained from Argiris, 
A., Karamouzis, M.V., Raben, D., Ferris. R.L. (2008). Lancet. 371, 1695-1709. (Argiris et 
al., 2008).  
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1.2 PI3K-PTEN-AKT/mTOR pathway 
The phosphoinositide-3-kinase (PI3K) pathway is perhaps the most frequently 
activated signaling pathway in human cancer. It plays a key role in the regulation of 
multiple cellular events, including cell growth, proliferation, cell cycle progression, and 
survival (Vivanco and Sawyers, 2002). PI3Ks phosphorylate the 3’-hydroxyl group of 
phosphatidylinositides. The PI3K family of enzymes is divided into three main classes 
(classes I-III), based on the structure and substrate specificity of each of the enzymes. 
Class I PI3Ks are those most often implicated in a wide array of human cancers 
(Engelman, 2009). In mammals, class I PI3Ks are further divided into subclasses, IA and 
IB, based on their modes of regulation. Class IA PI3Ks are heterodimers that comprise 
a regulatory subunit (p85), which mediates binding of the enzymatic ligand to membrane 
growth factor receptors, and one of four catalytic subunits (p110α, -β, -γ, or -δ), which 
are responsible for the activity of the enzyme (Engelman, 2009). The genes PIK3CA, 
PIK3CB, and PIK3CD encode the three highly homologous class IA catalytic isoforms: 
p110α, p110β, and p110δ, respectively. These isoforms associate with any of the five 
regulatory isoforms: p85α (and its splicing variants, p55α and p50α), p85β, and p55γ, 
which are collectively called p85-type regulatory subunits (Engelman et al., 2006). Class 
IB PI3Ks are heterodimers of a p110γ catalytic subunit, encoded by PIK3CG, coupled 
with the regulatory isoforms, p101 or p87 (Liu et al., 2009). Whereas p110α and p110β 
are ubiquitously expressed, p110δ and p110γ expression are generally restricted to 
leukocytes (Okkenhaug and Vanhaesebroeck, 2003).  
Activated by autocrine signaling, the PI3K/mTOR pathway plays a critical role in 
cancer cell activation and provides self-sustaining growth signals to tumors. The pathway 
can also be activated by paracrine signaling. In the absence of activating signals, p85 
interacts with p110 to inhibit p110 kinase activity. Following receptor tyrosine kinase 
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(RTK) or G protein-coupled receptor (GPCR) activation, class I PI3Ks are recruited to 
the plasma membrane, where p85-mediated inhibition of p110 is relieved and p110 
phosphorylates phosphatidylinositides 4,5-biphosphate (PIP2) to generate 
phosphatidylinositides 3,4,5-triphosphate (PIP3). The lipid product, PIP3, acts as a 
second messenger of the pathway. It can activate AKT-dependent and AKT-independent 
downstream signaling pathways (Vanhaesebroeck et al., 2010).  
AKT (protein kinase B) is a serine/threonine kinase expressed as three isoforms: 
AKT1, AKT2, and AKT3. All three isoforms share a similar structure: an N-terminal PH 
domain, a central serine/threonine catalytic domain, and a small C-terminal regulatory 
domain (Lu et al., 2012). Activation of AKT is initiated by its translocation to the plasma 
membrane, where the PH domain in the N-terminal region of the kinase docks to PIP3. 
This results in a conformational change in AKT, exposing two amino acid residues that 
are critical to the phosphorylation and activation of AKT. The full activation of AKT 
requires the phosphorylation of threonine 308 (Thr308) by PDPK1 (phosphoinositide-
dependent protein kinase 1) and the phosphorylation of serine 473 (S473) by PDPK2 
(phosphoinositide-dependent protein kinase 2) (Velichkova et al., 2010). Under most 
circumstances, mTORC2 is the primary source of PDPK2. Once activated, AKT 
phosphorylates various other proteins, including GSK3 (glycogen synthase kinase 3) and 
FOXOs (the forkhead family of transcription factors). Thus, AKT regulates a wide array 
of cellular processes involved in protein synthesis, cell survival, cell proliferation, and 
metabolism (Parsons, 2004). 
mTOR (mammalian target of rapamycin) belongs to a group of serine/threonine 
protein kinases that are referred to as class IV PI3Ks. The kinase serves as a pivotal 
regulator of cell growth, cell survival, and cell proliferation by monitoring nutrient 
availability, cellular energy and oxygen levels, and mitogenic signals (Song et al., 2012). 
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mTOR also plays a key role in tumorigenesis. mTOR exists in two structurally distinct 
complexes: mTORC1 and mTORC2. The mTORC1 complex is composed of the mTOR 
catalytic subunit, Raptor (regulatory associated protein of mTOR), PRAS40 (proline-rich 
AKT substrate 40 kDa), and the protein mLST8/GbL. mTORC2 is composed of mTOR, 
Rictor (rapamycin insensitive companion of mTOR), mSIN1 (mammalian stress-
activated protein kinase interacting protein 1), and mLST8/GbL (Chang et al., 1997). 
While mTORC1 controls protein synthesis by activating translation of proteins, mTORC2 
affects metabolism and cell survival by fully phosphorylating and thus activating AKT. 
However, mTORC2 is less defined than mTORC1.   
Partial AKT activation is sufficient to activate mTOR. AKT activates mTOR by 
directly phosphorylating tuberous sclerosis complex 2 (TSC2) to attenuate its inhibitory 
effects on mTOR1 (Klippel et al., 1996). The tuberous sclerosis complex (TSC), an 
essential negative regulator of mTORC1 activity, comprises tuberous sclerosis complex 
1 (TSC1; hamartin) and tuberous sclerosis complex 2 (TSC2; tuberin). TSC2 functions 
as a GTPase-activating protein (GAP) for Rheb. The active, GTP-bound form of Rheb 
directly interacts with mTORC1 to stimulate its activity. As a Rheb-specific GAP, TSC2 
negatively regulates mTORC1 signaling by converting Rheb into its inactive GDP-bound 
state. TSC1 does not have a GAP domain, but it acts as a stabilizer of TSC2 by protecting 
it from degradation (Klippel et al., 1996). Hence, the TSC complex functions as a tumor 
suppressor.  
The best characterized downstream targets of mTORC1 are S6K1 (p70S6 kinase) 
and eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4EBP1). Both 
effectors are critically involved in regulating protein synthesis and protein translation, 
respectively. S6K1 is a serine/threonine kinase that belongs to the family of AGC 
kinases. It is responsible for phosphorylating its core substrate, rpS6 (ribosomal protein 
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S6), resulting in cell growth and cell size regulation. While the activating phosphorylation 
of rpS6 at serines 240 and 244 (S240/244) are mediated by the PI3K/mTOR pathway, 
the activating phosphorylation of rpS6 at serines 235 and 236 (S235/236) are mediated 
by MEK/ERK pathway (Meyuhas, 2008). 4EBP1 is a member of a family of translation 
repressor proteins. It prevents translation initiation by binding to the translation factor, 
eIF4E. The interaction of hypo-phosphorylated 4EBP1 and eIF4E prevents its interaction 
with eIF4G, thereby blocking complex assembly and repressing translation. Inhibitory 
phosphorylation of 4EBP1 at serine 65 (S65) by mTORC1 causes its release from eIF4E, 
allowing cap-dependent translation to proceed (Ma et al., 2009). Thus, the activation of 
mTOR provides tumor cells with a growth advantage by promoting protein synthesis.  
The primary negative regulator of the PI3K pathway is the phosphatase and tensin 
homolog (PTEN). It negatively regulates the PI3K/mTOR pathway by removing the 3-
phosphate from PIP3, converting it back to PIP2 (Chia et al., 2010). PTEN is a lipid 
phosphatase that attenuates the proliferative phenotype of various types of cancer cells 
by antagonizing the activity of PI3K. Thus, PTEN serves as an essential tumor 
suppressor. Although PTEN is a highly stable protein, it is tightly regulated at the 
transcriptional level and is often regulated by post-translational modifications. While 
methylation of the promote region inactivates the PTEN gene, phosphorylation of PTEN 
at amino acid residues, serine 380 as well as threonines 382 and 383, inhibits protein 
activity (Salmena et al., 2008). A simplified illustration of the PI3K-PTEN-mTOR pathway 
is depicted in Figure 2. 
Genetic alterations in the PI3K pathway have been associated with a great deal 
of cancers. Hyperactivity of the PI3K pathway is one of the most prominent 
characteristics of many human tumors. Current research reports that pathway activity is 
upregulated in 30-50% of prostate cancers (De Velasco and Uemura, 2012; Suzuki et 
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al., 1998). Class IA PI3Ks are mutated and amplified in a wide array of cancer types. The 
PIK3CA gene encodes the p110α catalytic subunit of PI3K. It was found to be frequently 
mutated in 27% of breast cancers, 23% of endometrial cancers, 14% of colorectal 
cancers, 17% of urinary tract cancers, and 8% of ovarian cancers (Samuels et al., 2004). 
Most frequently activated mutations (also called “hot- spots”) in PI3K are located within 
the kinase domain, H1047, and the helical domains, E542 and E545 (Samuels et al., 
2004). 4-10% of esophageal squamous cell carcinomas exhibit activating mutations of 
PIK3CA. Mutations within the E542K and E545K hot-spots and the H1047R substitutions 
were the most common (Song et al., 2014). Furthermore, 40% of esophageal tumors 
present an increase in PIK3CA copy number, a feature that is associated with poor 
disease prognosis (Akagi et al., 2014; Lin et al., 2014; Song et al., 2014).  
One common mechanism promoting aberrant PI3K signaling is the somatic 
ablation of PTEN by genetic and epigenetic modifications. The PTEN gene maps to the 
human chromosome 10q23.3, a region that displays high rates of heterozygosity loss in 
various cancer types, including kidney, lung, breast, and prostate cancer (Kwabi-Addo 
et al., 2001). Previous research suggests that in aggressive forms of prostate cancer, 
the PTEN gene is subject to DNA sequence alterations and point mutations that inhibit 
the activity of the PTEN protein (Dong, 2006). Ablation of PTEN often results in 
unrestrained signaling of the PI3K pathway, which may lead to tumorigenesis. In fact, 
loss of PTEN in most cancer types leads to hyper-activation of AKT, which is associated 
with uncontrollable cell proliferation, decreased apoptosis, and enhanced tumor 
angiogenesis (Carnero et al., 2008).  Taken together, the findings suggest that the loss 
of the tumor suppressive function of PTEN is critically linked to tumorigenesis and cancer 
progression.  
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Figure 2: The PI3K-PTEN-AKT/mTOR pathway.  
Activation of the PI3K/mTOR pathway via endogenous stimuli, exogenous signals, or 
mutations promotes cell growth, proliferation, cell cycle progression, and survival. The 
PI3Ks are a complex of heterodimers that encompass regulatory and catalytic subunits. 
Upstream cellular receptors (such as RTKs and GPCR) promote the activation of the 
PI3Ks, which initiates a downstream signaling cascade via phosphorylation. The PI3Ks 
phosphorylate the membrane phospholipid substrate, PIP2, converting it into PIP3. PTEN 
is a phosphatase that reverts the activity of PI3K by removing the 3-phosphate from PIP3, 
converting it back to PIP2. Therefore, an inactivating mutation or loss of PTEN leads to 
hyper-activation of the PI3K/mTOR pathway. PIP3 then recruits AKT to the plasma 
membrane, where PDK1 and PDK2 fully activate AKT by phosphorylating Thr308 and 
S473, respectively. Once activated, AKT phosphorylates and inhibits the TSC1/2, 
leading to the activation of the mTOR complex (mTORC1 and mTORC2). Activated 
mTORC1 phosphorylates downstream effectors, S6K1 and 4EBP1. Thus, the PI3K-
PTEN-mTOR pathway can control essential cancer cell processes, including 
proliferation, invasion, metastasis, and response to therapy. Permission obtained from 
Giudice, F., and Squarize, C. (2013). J Carcinogene Mutagene. S5: 003. (Giudice et al., 
2013).  
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1.3 PI3K-PTEN-AKT/mTOR pathway in HNSCC 
The PI3K/AKT/mTOR pathway plays a key role in regulating several cellular 
processes in normal and cancer cells, including proliferation, growth, invasion, migration, 
and survival. Currently, the PI3K/AKT/mTOR is the most frequently altered pathway in 
HNSCC. Approximately 80% of HNSCC tumors contain genetic alterations in one or 
more components of the pathway (Iglesias-Bartolome et al., 2013; Lui et al., 2013). 
According to the most current data produced by the head and neck cohort of The Cancer 
Genome Atlas (TCGA), 18% of 510 HNSCC tumors exhibit mutations in the PIK3CA 
gene (Gao et al., 2013). The frequency of the pathway alterations promotes poor disease 
prognosis.  
In HNSCC, particularly, the type and frequency of genetic alterations in the 
PI3K/mTOR pathway vary immensely. Many of the alterations occur in the PIK3CA gene. 
Findings of recent research report gain-of-function mutations in PIK3CA in 6-20% of 
tumors. Other studies report PIK3CA overexpression in 52% of tumors and PIK3CA 
amplification in 30% of tumors. The hot-spot substitutions, E542K, E545K, and H1047R, 
were the most common (Agrawal et al., 2011; Stransky et al., 2011; Suda et al., 2012; 
Lui et al., 2013). Some of the alterations also occur in PTEN, both at the gene and protein 
levels. Previous research findings report loss of heterozygosity (LOH) of PTEN in 8% of 
tumors and inactivating PTEN mutations in 4% of tumors. Likewise, reduced PTEN 
protein expression occurred in 30% of tumors (Squarize et al., 2013; Morris et al., 2011). 
There were also mutations in the PIK3CG gene in 4% of tumors (Agrawal et al., 2011; 
Stransky et al., 2011). Furthermore, while mutations in the AKT and mTOR genes occur 
rarely, phosphorylation of AKT and S6 at the protein level are frequently exhibited in 
almost all HNSCC tissues (Lui et al., 2013; Molinolo et al., 2007). This phosphorylation 
is an indication of constitutive pathway activation.  
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1.4 PI3K/mTOR pathway inhibition in HNSCC 
The frequent activation of the PI3K/mTOR pathway in HNSCC and the pathway’s 
significant effect of cancer cell signaling make it a promising target for desperately 
needed improvements in various cancer therapies. Because the pathway’s activation is 
regulated by identifiable genetic alterations, it is important to use suitable biomarkers for 
predicting response to those therapies. For these reasons, many pharmaceutical 
companies and academic laboratories are actively developing inhibitors to target the 
entire pathway and its key components. Wortmannin and LY294002 are two well-known, 
first generation PI3K inhibitors. Wortmannin binds irreversibly binds to PI3K enzymes by 
covalently modifying a lysine necessary for catalytic activity, while LY294002 is a small-
molecule inhibitor that reversibly targets the PI3K family members (Liu et al., 2009). 
Unfortunately, both inhibitors have miniscule selectivity for the distinct isoforms of PI3K 
and are rather toxic in animals (Knight and Shokat, 2007). Despite their limitations, the 
preclinical studies influenced by the inhibitors have greatly contributed to our 
understanding of the biological significance of the PI3K pathway.  
Several compounds targeting PI3K activity have been introduced into clinical 
trials, with many of them being dual PI3K/mTOR inhibitors. BEZ235 inhibits multiple class 
I PI3K isoforms and mTOR kinase activity by binding to the ATP-binding pocket (Maira 
et al., 2008). Preclinical data suggests that it displays strong anti-proliferative properties 
on tumor xenografts that exhibit many key genetic alterations in the PI3K pathway, 
including PTEN ablation and gain-of-function PI3K mutations (Serra et al., 2008). 
BEZ235 has entered Phase I clinical trials in patients with solid tumors (Garcia-
Echeverria and Sellers, 2008). BGT226 and BKM120, a selective class I PI3K inhibitor 
with no inhibitor effects on mTOR activity, have also entered Phase I clinical trials (Knight 
and Shokat, 2007).  
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Previous studies report that head and neck tumors with activating alterations in 
PIK3CA respond better to targeted therapies with specific PI3Kα inhibitors (Elkabets et 
al., 2013; Mazumdar et al., 2014). Of note, the first-in-human clinical trial of BYL719, a 
specific PI3Kα inhibitor, in solid tumors (NCT01387321) reported that eight patients with 
head and neck tumors harboring PI3KCA mutations had a clinical response to therapy 
(Baselga et al., 2014, Annals of Oncology, abstract). Despite the frequent activation of 
the PI3K/mTOR pathway in HNSCC, using various chemical inhibitors to attenuate 
pathway activity has resulted in variable efficacy in vitro and in vivo.  
 
1.5 NOTCH pathway 
 The NOTCH signal transduction pathway assumes numerous roles in various 
developmental processes. NOTCH signaling serves as a critical determinant of cellular 
fate within a vast array of tissues. The pathway regulates cell growth, differentiation, and 
apoptosis (Artavanis-Tsakonas et al.,1999). Activated by juxtacrine signaling, the 
interaction between the receptor of the signal-receiving cell and the ligand of the signal-
sending cell activates the signaling cascade of the NOTCH pathway. There are four 
mammalian NOTCH receptors (NOTCH1-4). The receptors are evolutionarily conserved 
single-pass, heterodimeric transmembrane proteins composed of an extracelluar 
(NECD) domain, a transmembrane (NTM) domain, and a NOTCH1 intracellular (NICD) 
domain. Additionally, there are five ligands: Delta-like (Dll-1, Dll-3, and Dll-4) and Jagged 
(Jagged-1 and Jagged-2), all of which are expressed on adjacent cells (Hansson et al., 
2004). Figure 3 depicts the canonical NOTCH pathway. 
Upon activation of the pathway, the ligand of the neighboring cell binds to the 
receptor of the NOTCH pathway, initiating a signaling cascade within the pathway. In the 
signal-receiving cell, NOTCH receptors are processed in the endoplasmic reticulum and 
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the Golgi apparatus via glycosylation and the first proteolytic cleavage, generating a 
calcium-stabilized heterodimer. The heterodimer, which consists of the NECD that is 
non-covalently attached to the TM-NICD complex, is transported to the plasma 
membrane of the cell by endosomes (Weinmaster, 1997). The receptor then undergoes 
two subsequent ligand-dependent proteolytic cleavages events. The second proteolytic 
cleavage involves tumor necrosis factor-α-converting enzyme (TACE), a transmembrane 
protein that includes an extracellular zinc-dependent protease domain. TACE cleaves 
the extracellular site of the NOTCH receptor between amino acid residues, alanine 1710 
and valine 1711, leaving the NECD bound to the ligand of the signal-sending cell (Mumm 
and Kopan, 2000).  
The third proteolytic cleavage involves γ-secretase, an integral membrane protein 
that cleaves transmembrane proteins at amino acid residues within the transmembrane 
domain. The γ-secretase complex consists of presenilin, nicastrin, Pen-2, and Aph-1. 
The γ-secretase complex cleaves the intracellular region of the receptor, releasing the 
active form of NICD (Bray, 2006). NICD is then released into the cytoplasm, where it is 
subsequently translocated into the nucleus to establish NOTCH signaling and begin 
transcription. In the absence of NICD from the nucleus, the NOTCH target gene 
expression is inactivated by a complex referred to as “CSL.” The complex encompasses 
a transcriptional repressor protein called C protein binding factor 1 (CBF1), Suppressor 
of hairless [Su(H)], and Lag1. Once NICD is present in the nucleus, it binds to the CSL 
complex, converting CBF1 from a transcriptional repressor to a transcriptional activator 
and displacing the other co-repressors (Weinmaster, 1997).  
The CSL-NICD complex then recruits a co-activator complex that contains 
Mastermind (MAML) and p300. Mastermind (MAML) is a 3-member family of 
transcriptional activator proteins. p300 is a histone acetyltransferase that epigenetically 
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modifies that structure of chromatin to a form that is amenable to active transcription. 
Once the complexes bind efficiently in the nucleus, the NOTCH pathway is fully activated 
and transcription takes place (Wu et al., 2000). The NOTCH target genes include AKT, 
mTOR, and HES/HEY family members. AKT and mTOR are key components of the 
PI3K/mTOR pathway.  
HES1 (hairy enhancer of split-1) is one of ten members (HES1-7; HEY1, HEY2, 
HEYL) of the HES and HEY families. HES and HEY genes encode nuclear proteins that 
suppress transcription. Like HEY1 (hairy enhancer-of-split related with YRPW motif 
protein 1), HES1 belongs to the basic helix-loop-helix (bHLH) families of transcription 
factors (Leimeister et al., 1999). It represses the transcription of genes that require the 
function of a bHLH protein for their transcription. The HES1 protein has a certain type of 
domain that contains a helix interrupting protein that binds to the N-box promoter region 
of the respective gene, rather than the canonical enhancer box (E-box) (Kageyama et 
al., 2007). As a member of the bHLH family, HES1 is a transcriptional repressor that 
regulates many cellular processes that influence development. It plays a pivotal role in 
cell proliferation and differentiation in embryogenesis (Kageyama et al., 2008). 
 The NOTCH1 pathway is complex because it can assume different roles in 
different cancer types. NOTCH1 can act as an oncogene or a tumor suppressor, 
depending on the context of the cancer. It is well-documented in the literature NOTCH1 
functions as an oncogene in various types of leukemias and lymphomas. NOTCH1 was 
first identified as an oncogene in T-cell acute lymphoblastic leukemia, where activating 
NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) led to ligand-
independent NOTCH1 signaling (Weng et al., 2004). NOTCH1 exhibits oncogenic 
signaling in approximately 60% of human T-ALL tumors (South et al., 2012). The same 
role was later established in other B cell malignancies, such as chronic lymphocytic 
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leukemia (CLL) and mantle cell lymphoma (MCL), and breast adenocarcinomas. While 
NOTCH1 functions as an oncogene in 5-12% of CLL tumors and approximately 10% of 
MCL tumors, it functions as an oncogene in less than 5% of breast adenocarcinomas 
(South et al., 2012).  
NOTCH1 serves as a tumor suppressor in many different types of squamous cell 
carcinomas (SCCs). The tumor suppressor role of NOTCH1 signaling was first reported 
by the Radtke group. Their research showed that conditional knock out of NOTCH1 
increased tumor incidence in squamous cell skin carcinomas (Radtke and Raj, 2003). 
Currently, active NOTCH1 signaling exerts tumor suppressive properties on 60-70% of 
squamous cell skin carcinomas. Additionally, NOTCH1 functions as a tumor suppressor 
in 5-10% of lung squamous cell carcinoma tumors (South et al., 2012). The diverse 
function of NOTCH1 in the context of a cancer cell renders it a novel targeting agent for 
improving modern cancer therapies.  
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Figure 3: The NOTCH pathway.  
The NOTCH pathway plays a key role in regulating cell fate determination, cell 
differentiation, and apoptosis. Upon activation, the intracellular domain of the NOTCH1 
receptor (NICD) is cleaved. NICD then enters the cytoplasm and is translocated to the 
nucleus, where it aids in the transcription of various target genes. Permission obtained 
from Amsen, D., Antov, A., Flavell, R. A. (2009). Nature Reviews Immunology. 9, 116-
124. (Amsen et al., 2009). 
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1.6 NOTCH1 pathway in HNSCC 
Understanding the NOTCH1 pathway is essential to developing targeted 
therapies for head and neck squamous cell carcinoma. Multiple groups have performed 
whole exome sequencing on head and neck tumors and discovered frequent NOTCH1 
mutations in HNSCC (Agrawal et al., 2011; Stransky et al., 2011; Pickering et al., 2013). 
These findings were confirmed by the most current data produced by the head and neck 
cohort of The Cancer Genome Atlas (TCGA), in which NOTCH1 mutations have a 
prevalence of approximately 18% in 510 HNSCC patient tumor samples (Gao et al., 
2013). Of note, the majority of mutations are predicted to be inactivating NOTCH1 
mutations. Findings of recent research identified a pattern of truncating NOTCH1 
mutations that occurred frequently in HNSCC. Particularly, 28 NOTCH1 mutations in 21 
patients with HNSCC tumors predicted tumor suppressive properties (Agrawal et al., 
2011).  
More specifically, the oncogenic NOTCH1 mutations exhibited by T-ALL occur in 
two locations along the gene. The first hot-spot consists of generally missense mutations 
within the negative regulatory heterodimerization domain. The second hot-spot consists 
of frequent truncating mutations near the C-terminus, leading to a deletion in the PEST 
domain and causing a markedly increased stabilization of constitutively activated 
NOTCH1 in the nucleus (Ferrando, 2009). In HNSCC, however, the distribution of 
inactivating NOTCH1 mutations is completely different from the activating NOTCH1 
mutations found in T-ALL. There are some truncating mutations dispersed throughout 
the gene, but they are not located in the PEST domain. Most of the missense mutations 
cluster in the extracellular EGF-like binding domain, thereby preventing the NOTCH1 
receptor from binding to the ligand and blocking NOTCH1 signaling (Pickering et al., 
2014). The findings suggest that the NOTCH1 mutations in HNSCC are loss-of-function 
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mutations. Figure 4 is an illustration of the locations of the mutations in T-ALL and 
HNSCC along the NOTCH1 gene.  
The results of the next generation sequencing analysis on HNSCC tumors and 
the mutational landscaping of NOTCH1 in both cancer types support the hypothesis that 
NOTCH1 functions as a tumor suppressor in head and neck squamous cell carcinoma, 
unlike its well-established role as an oncogene in T-ALL. Researchers subsequently 
demonstrated that restoring NOTCH1 receptors with active NOTCH1 signaling to 
NOTCH1 mutant HNSCC cell lines inhibited their in vitro growth on external ligands as 
well as their in vivo growth in mice (Pickering et al., 2013). Currently, inactivating 
NOTCH1 mutations have been discovered in a vast number of solid tumors derived from 
skin, lung, and esophageal squamous cell carcinomas (Pickering et al., 2014; group Tw, 
2012; Agrawal et al., 2012). Taken together, the findings support the observation that 
NOTCH1 is one of the most frequently occurring and commonly mutated novel genes in 
HNSCC (Agrawal et al., 2011).  
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Figure 4: Genetic locations of NOTCH1 mutations in T-ALL and HNSCC.  
There are different patterns of NOTCH1 mutations in T-ALL and HNSCC. Missense, 
truncating, and in-frame indel mutations are indicated with green, black, and brown dots, 
respectively. The NOTCH1 domains are color-coded, with the heterodimerization (HD) 
and Lin-NOTCH repeat (LNR) domains constituting negative regulatory regions 
(Pickering et al., 2014; Figure: Mitchell J. Frederick, PhD).  
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1.7 Sensitivity of NOTCH1 mutants to PI3K/mTOR inhibitors  
 
To identify novel, translationally applicable molecular vulnerabilities to  
PI3K/mTOR pathway inhibitors, our laboratory used a pharmacogenomics approach to 
integrate drug sensitivity data for seven diverse PI3K/mTOR pathway inhibitors with 
multiple ‘omic’ data on a panel of molecularly characterized HNSCC cell lines. The 
association between drug response and molecular characteristics in the respective cell 
lines was studied. Sixty-eight head and neck squamous cell carcinoma cell lines were 
analyzed. They were stratified into 3 groups, based on their genotype. The cell lines were 
treated with 2 dual PI3K/mTOR inhibitors, exclusively, and cell viability was measured. 
Based on the best dose-response model, IC 70 values were generated for each cell line.  
The same cell lines were also treated with selective class I PI3K and pan-PI3K 
inhibitors. The drug screening experiments in the laboratory revealed that the cell lines 
that harbored NOTCH1 and PIK3CA mutations were more sensitive to the selective class 
I PI3K, the pan-PI3K, and the dual PI3K/mTOR inhibitors than their wild-type 
counterparts. Drug-induced apoptosis was also measured. The cell lines treated with 
dual PI3K/mTOR inhibitors exhibited significant increases in cell death. The results, 
however, were irrespective of the PIK3CA status of the cell lines. NOTCH1 mutant 
HNSCC cells lines were sensitive to dual PI3K/mTOR inhibitors and underwent 
apoptosis. An independent study reported that NOTCH1 mutant tumors found in two 
HNSCC patient derived xenografts (PDXs) were sensitive to a PI3K inhibitor in vivo 
(Keysar et al., 2013). The preclinical data produced by our lab suggests that HNSCC 
patients with NOTCH1 mutations may have an even better response to PI3K/mTOR 
inhibitors than those patients that harbor PIK3CA mutations.  
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1.8 Potential NOTCH1 and PI3K-PTEN-AKT/mTOR interactions  
The interaction between the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways  
is well known in T-ALL. Constitutively active NOTCH1 signaling contributes to more than 
half of all cases of T-ALL (Weng et al., 2004). Initially, using γ-secretase inhibitors (GSIs) 
to block the proteolytic cleavage of NOTCH1 proved effective in inducing cellular growth 
arrest and apoptosis in some T-ALL cell lines. However, the GSI treatment failed to 
prevent the growth of NOTCH1 mutant T-ALL cell lines. The findings suggest a 
mechanism of resistance that NOTCH1 mutant T-ALL cell lines employ to overcome 
various therapies. Subsequent research demonstrates that in T-ALL cell lines, a key 
indicator of resistance to GSI-mediated NOTCH1 inhibition is homozygous loss of PTEN. 
Studies further show that PTEN expression is negatively regulated by HES1, a pivotal 
downstream target of the NOTCH1 pathway (Palomero et al., 2007). Additionally,                    
γ-secretase-mediated NOTCH1 inhibition was shown to be synergistic with the inhibition 
of mTOR, a downstream effector of PI3K/AKT signaling, in T-ALL cell lines. The results 
were irrespective of the cell lines’ sensitivity to the GSI treatment (Chan et al., 2007). 
 In some T-ALL cases, for instance, active NOTCH1 signaling leads to the 
transcriptional repression of PTEN and subsequent activation of the PI3K/AKT/mTOR 
pathway, which leads to cell survival and proliferation. In other T-ALL cases, NOTCH1 
inhibition leads to upregulated PTEN that inhibits the PI3K/AKT/mTOR pathway and 
results in cell growth arrest and apoptosis. Additionally, T-ALL tumor cells survive and 
proliferate when both pathways are activated and no PTEN is present. Furthermore,   
T-ALL tumors that lack PTEN and active NOTCH1 signaling retains active 
PI3K/AKT/mTOR pathway signaling that promotes cellular survival and proliferation 
(Gutierrez and Look, 2007). The findings support a common indication: PTEN must be 
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present in the cell to inhibit the PI3K/AKT/mTOR pathway and prevent cell proliferation 
and survival.  
Presumably, T-ALL tumors that possess mutations or deletions in PTEN are 
capable of constitutively inhibiting PTEN via the NOTCH1-HES1 pathway. The genetic 
alteration renders the cells resistant to GSIs by preventing the reactivation of PTEN, 
which typically occurs when NOTCH signaling is blocked. The findings also suggest that 
PTEN serves as a prominent mediator of communication between the NOTCH1 and 
PI3K/AKT/mTOR pathways in T-ALL. The interaction between both pathways is largely 
unknown in HNSCC. Because NOTCH1 has a different role in T-ALL than it does in 
HNSCC, the interactions may also be distinct. Elucidating the mechanism of 
communication between the NOTCH1 and PI3K/AKT/mTOR pathways in HNSCC may 
aid in the development of target therapies for patients with HNSCC tumors. After all, 
there are no effective targeted therapies for cancers driven by the loss of tumor 
suppressive properties. 
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1.9 Central Hypothesis and Specific Aims 
 
The central goal of the project was to elucidate the mechanism of communication 
between the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways in HNSCC.  More 
specifically, we investigated whether the NOTCH1 pathway regulates the activity of the 
PI3K-PTEN-AKT/mTOR pathway in HNSCC in vitro. Figure 5 is a diagram of the potential 
interaction between the NOTCH1 pathway and the PI3K-PTEN-AKT/mTOR pathway in 
HNSCC in vitro. We hypothesized that NOTCH1-mediated upregulation of HES1 
promotes downregulation of PTEN transcription and activation of the PI3K/AKT/mTOR 
pathway in HNSCC.  
Specific Aim 1: To determine if HES1 is regulated by NOTCH1 signaling in 
HNSCC cell lines.   
A. To determine if basal levels of HES/HEY family members are different in 
NOTCH1 mutant and wild-type HNSCC cell lines 
We collaborated with the Department of Bioinformatics and Computational Biology who 
applied modified two-sample t-tests analyses to cleaved NOTCH1 (NICD) reverse phase 
protein array (RPPA) values and HES/HEY RNA sequence (RNA-seq) values to identify 
differentially expressed variables between the comparative groups. They also applied 
Spearman correlation and Pearson correlation analyses to the data sets to identify 
correlated variables between the comparative groups. We hypothesized that there would 
be a direct positive correlation between mRNA expression of each of the HES and HEY 
family members and cleaved NOTCH1 status. 
B. To determine if levels of HES1 change when we inhibit NOTCH1 signaling 
in NOTCH1 wild-type HNSCC cell lines 
We employed three methods of manipulation to inhibit NOTCH1 signaling in NOTCH1 
wild-type HNSCC cell lines. We (1) blocked NOTCH1 signaling using OMP-52M51, a 
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NOTCH1 monoclonal blocking antibody; (2) silenced NOTCH1 gene expression using 
siRNA targeting the NOTCH1 receptor gene; and (3) obtained NOTCH1-/- cell lines from  
Dr. Mitchell Frederick’s laboratory. We measured NOTCH1 pathway, HES1, and PI3K-
PTEN-AKT/mTOR pathway protein levels via western blot. We also measured NOTCH1, 
HES1, and PTEN mRNA levels via qRT-PCR. We hypothesized that inhibiting NOTCH1 
signaling would downregulate HES1 gene and protein expression, leading to upregulated 
PTEN transcription and protein activity, and the subsequent inactivation of the 
PI3K/AKT/mTOR pathway.  
C. To determine if levels of HES1 change when we induce NOTCH1 signaling in 
NOTCH1 mutant HNSCC cell lines 
We administered doxycycline to induce the NOTCH1 intracellular domain (NICD) 
expression system in NOTCH1 mutant HNSCC cell lines. We measured NOTCH1 
pathway, HES1, and PI3K-PTEN-AKT/mTOR pathway protein levels via western blot. 
We also measured NOTCH1, HES1, and PTEN mRNA levels via qRT-PCR. We 
hypothesized that restoring active NOTCH1 signaling would upregulate HES1 gene and 
protein expression, leading to downregulated PTEN transcription and protein activity, 
and the subsequent hyper-activation of the PI3K/AKT/mTOR pathway.  
Specific Aim 2: To determine if HES1 regulates the PI3K-PTEN-/AKT/mTOR 
pathway. 
A. To determine if PI3K-PTEN-AKT/mTOR pathway target protein levels 
change when we silence HES1 gene expression in NOTCH1 wild-type HNSCC cell lines 
We silenced HES1 gene expression in NOTCH1 wild-type HNSCC cell lines using siRNA 
targeting the HES1 gene. We measured NOTCH1 pathway, HES1, and PI3K-PTEN-
AKT/mTOR pathway protein levels via western blot. We also measured NOTCH1, HES1, 
and PTEN mRNA levels via qRT-PCR. We hypothesized that silencing the HES1 gene 
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would downregulate HES1 protein expression, upregulate PTEN transcription and 
protein activity, and lead to the subsequent inactivation of the PI3K/AKT/mTOR pathway. 
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Figure 5: Potential NOTCH1 and PI3K-PTEN-AKT/mTOR pathways interaction. 
Active NOTCH1 signaling will lead to the active transcription of HES1 and subsequently 
upregulate HES1 gene expression. In turn, HES1 will transcriptionally repress PTEN 
transcription and subsequently downregulate PTEN gene expression. The ablated 
activity of PTEN will lead to the hyper-activation of the PI3K/AKT/mTOR pathway. 
(Figure: Vaishnavi Sambandam, PhD).  
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2.1 HNSCC Cell Lines 
 A panel of 68 HNSCC cell lines were obtained from sources delineated in (Zhao 
et al., 2011) and maintained as directed. The cell lines were profiled for authenticity by 
Short Tandem Repeat (STR) analysis. They were tested for mycoplasma contamination 
using a Mycoplasma detection kit (Lonza). All cell lines were mycoplasma free at the 
time of testing. The assembly, characterization, and STR profiles for all of the cell lines 
are also described in (Zhao et al., 2011). The CRISPR/Cas9 knock out cell lines and the 
doxycycline inducible Notch1 intracellular domain (NICD) expression system were 
developed by Dr. Mitchell Frederick’s laboratory.  
 
2.2 Cell Culture 
 All cells were cultured in 1X Dulbecco's Modified Eagle's Medium (DMEM) 
complete media containing 10% FBS, 2% Penicillin/Streptomycin, L-glutamine, glucose, 
and sodium pyruvate (Corning). Cells were incubated in a 37°C, 5% carbon dioxide 
incubator.  
 
2.3 Western blotting 
 HNSCC cell lines were lysed with 1X Cell Lysis Buffer (20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 
1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin; Cell Signaling Technology). 
After lysing, cells were incubated on ice and allowed to solubilize in the buffer for 15 
minutes. The lysates were then centrifuged at 14,000 x g at 4°C for 15 minutes. The 
supernatant was collected and protein concentration was measured using the Pierce 
BCA protein assay kit (ThermoFisher Scientific). The lysates were then mixed with 10% 
β-mercaptoethanol and 4X Laemmli protein sample buffer (Bio-Rad) and loaded onto 4-
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20% gradient gels (Mini-PROTEAN TGX Precast Gels; Bio-Rad), based on the 
molecular weights of the probed proteins. Gels were run using 10X premixed gel 
electrophoresis buffer (25mM Tris, 192 mM glycine and 0.1%SDS at pH 8.3, after mixing 
with distilled water; Bio-Rad) at 115 V for 1.5-2 hours. Gels were then turbo-transferred 
on nitrocellulose membranes using the Trans-Blot Turbo 5X Transfer Buffer (Bio-Rad) 
for 30 minutes in the Trans-Blot Turbo Transfer System (Bio-Rad). After transfer, the 
membranes were blocked using 5% milk in TBST for 2 hours with constant rotating 
agitation. The membranes were then incubated with the respective primary antibodies at 
various concentrations, ranging from 1:1000-1:10000, depending on the binding affinities 
of the antibodies. The membranes were then incubated overnight at 4°C with constant 
rotating agitation. After incubation, the membranes were washed for 15 minutes with 
washing buffer, TSBT containing 0.1% Tween-20, approximately 3 times. Membranes 
were then incubated with the respective species-specific horseradish peroxidase-
conjugated secondary antibodies for 1 hour at room temperature with constant rotating 
agitation. Protein signals were developed using the Pierce ECL Western Blotting 
Substrate or the SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher 
Scientific), depending on the strength of the protein signals, on an X-ray film. Relative 
protein abundance was quantified using ImageJ (Schneider et al., 2012) and the 
expression of each protein was normalized against the internal control protein, β-actin, 
using the formula, [(target protein value)/(actin value)]. The fold change of protein 
expression was calculated using the formula, [(B)/(A)], in which “B” represents the treated 
condition of each protein normalized against β-actin and “A” represents the control 
condition of each protein normalized against β-actin. 
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2.4 Quantitative reverse transcription PCR (qRT-PCR) 
 Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen). Cells were 
briefly scrapped from the petri dish using a scraper after adding the Buffer RLT Plus 
RNeasy Plus lysis buffer solution (Qiagen). The sample lysates were homogenized for 3 
minutes using a QIAshredder (Qiagen). The lysates were then mixed with ethanol and 
applied to a silica-based filter, which selectively binds mRNA and larger rRNA. The filter 
was washed with Buffer RW1 and Buffer RPE wash buffers (Qiagen) to remove residual 
DNA and other contaminants. The RNA is then eluted from the filter with nuclease-free 
water. RNA concentration was measured using the NanoDrop 2000c spectrophotometer 
(Thermo Scientific). cDNA was then synthesized by reverse transcription using the iScript 
cDNA Synthesis Kit (Bio-Rad) in a MJ Mini personal thermal cycler (Bio-Rad) as directed 
by the manufacturer. A total of 100ng of cDNA was used per reaction, and each reaction 
was measured in triplets using a C1000 Touch Thermal Cycler (Bio-Rad). The 
expression of each target gene was normalized against the internal control gene, 
GAPDH, calculated using the formula, [2^(GAPDH value)-(target protein value)]. The fold 
change of gene expression was calculated using the formula, [(B)/(A)], in which “B” 
represents the treated condition of each gene normalized against GAPDH and “A” 
represents the control condition of each gene normalized against GAPDH. 
 
2.5 Transfection  
 siRNA transfections were performed using HNSCC cells. Cells were plated at a 
density of 2.0x106 the day before transfection. On the day of the transfection, 
Lipofectamine RNAiMAX transfection reagent (Invitrogen, Life Technologies) was diluted 
in 1X OPTI-MEM Reduced Serum Media (Gibco, Life Technologies). In a separate 
Eppendorf tube, the respective siRNA was diluted in 1X OPTI-MEM Reduced Serum 
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Media. The diluted siRNA solution was then added to the diluted Lipofectamine 
RNAiMAX reagent solution (1:1 ratio) and incubated at room temperature for 5 minutes. 
The siRNA-lipid complex was then added to the cells, which were incubated in a 37°C, 
5% carbon dioxide incubator for 24 hours. Protein lysates were then collected at the 24-
hour time point and analyzed via western blot and qRT-PCR.  
 
2.6 Chemical inhibition 
 Brontictuzumab (OMP-52M51), a humanized IgG monoclonal antibody against 
NOTCH1, was obtained from OncoMed Pharmaceuticals, Inc. Normal mouse IgG, an 
isotype control immunoglobulin, was obtained from Santa Cruz Biotechnology, Inc (# sc-
2025). Drug treatments via chemical inhibition were performed using HNSCC cells. Cells 
were plated at a density of 2.0x106 the day before drug administration. On the day of the 
treatment, OMP-52M51 and normal mouse IgG were added to the experimental and 
control cells, respectively, at a concentration of 0.5ug/ml. The cells were then incubated 
in a 37°C, 5% carbon dioxide incubator for 30 minutes, 2 hours, 4 hours, 8 hours, and 
24 hours. Protein lysates were then collected at each of the time points and analyzed via 
western blot and qRT-PCR. 
 
2.7 siRNAs for NOTCH1 and HES1 
 The non-targeting control and NOTCH1 siRNAs were obtained from Dharmacon 
(GE Life Sciences). Each pool contained four sequences for each gene. The antisense 
sequences for the ON-TARGETplus Non-targeting Pool are:  
1) UGGUUUACAUGUCGACUAA 
2) UGGUUUACAUGUUGUGUGA 
3) UGGUUUACAUGUUUUCUGA 
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4) UGGUUUACAUGUUUUCCUA 
The antisense sequences for the NOTCH1 ON-TARGETplus SMARTpool are: 
1) GCGACAAGGUGUUGACGUU 
2) GAUGCGAGAUCGACGUCAA 
3) GGACAUCACGGAUCAUAUG 
4) GAACGGGGCUAACAAAGAU 
The HES1 siRNA was obtained from Santa Cruz Biotechnology, Inc (# sc-270146). The 
construct consists of a pool of three target-specific, 19-25 nucleotide sequences 
designed to silence gene expression.  
 
2.8 Antibodies 
 The antibodies utilized in this project are outlined in Table 1. 
 
Antibody Source Catalog  
No. 
Conc. Diluent 
NOTCH1-NTM Cell Signaling 3439 1:1000 5% BSA + 0.03% NaN3 – TBST 
NOTCH2-NTM Cell Signaling 5732 1:1000 5% BSA + 0.03% NaN3 – TBST 
NOTCH3-NTM Cell Signaling 5276 1:1000 5% BSA + 0.03% NaN3 – TBST 
NOTCH4-NTM Cell Signaling 2423 1:1000 5% BSA + 0.03% NaN3 – TBST 
Cleaved 
NOTCH1 
Cell Signaling 4147 1:1000 5% BSA + 0.03% NaN3 – TBST 
HES1 Cell Signaling 11988 1:1000 5% BSA + 0.03% NaN3 – TBST 
Phospho-PTEN 
(Ser380/ 
Thr382/383) 
 
Cell Signaling 
 
9549 
 
1:1000 
 
5% BSA + 0.03% NaN3 – TBST 
PTEN Cell Signaling 9552 1:1000 5% BSA + 0.03% NaN3 – TBST 
Phospho-AKT 
(Ser473) 
Cell Signaling 4060 1:1000 5% BSA + 0.03% NaN3 – TBST 
Total AKT Cell Signaling 4691 1:1000 5% BSA + 0.03% NaN3 – TBST 
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Phospho-S6 
(Ser235/236) 
Cell Signaling 2211 1:1000 5% BSA + 0.03% NaN3 – TBST 
Phospho-S6 
(Ser240/244) 
Cell Signaling 2215 1:1000 5% BSA + 0.03% NaN3 – TBST 
Total S6 Cell Signaling 2217 1:1000 5% BSA + 0.03% NaN3 – TBST 
Phospho-4EBP1 
(Ser65) 
Cell Signaling 13443 1:1000 5% BSA + 0.03% NaN3 – TBST 
Total 4EBP1 Cell Signaling 9452 1:1000 5% BSA + 0.03% NaN3 – TBST 
β-actin Cell Signaling 3700 1:10000 5% BSA + 0.03% NaN3 – TBST 
 
Table 1: Description of the antibodies used in the project.  
 
2.9 Primers 
 The primers utilized in this project are outlined in Table 2. 
 
Gene Source Target Sequence(5’-3’) 
 
GAPDH 
 
Sigma-Aldrich 
 
Forward: CCCATCACCATCTTCCAG 
 
Reverse: ATGACCTTGCCCACAGCC 
 
 
NOTCH1 
 
Sigma-Aldrich 
 
Forward: TCCACCAGTTTGAATGGTCA 
 
Reverse: AGCTCATCATCTGGGACAGG 
 
 
HES1 
 
Sigma-Aldrich 
 
Forward: CCCAACGCAGTGTCACCTTC 
 
Reverse: TACAAAGGCGCAATCCAATATG 
 
 
PTEN 
 
Sigma-Aldrich 
 
Forward: CCAGGACCAGAGGAAACCT 
 
Reverse: GCTAGCCTCTGGATTTGA 
 
 
Table 2: Description of the primers used in the project. 
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CHAPTER 3: RESULTS AND ANALYSES 
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3.1 HES5 mRNA expression is lower in NOTCH1 mutant than NOTCH1 wild-type 
HNSCC cell lines 
 Previous research suggests that HES1 transcriptionally represses PTEN, leading 
to the hyperactivity of the PI3K/AKT/mTOR pathway and increased cell growth, survival, 
and proliferation (Gutierrez and Look, 2007; Palomero et al., 2007). Because HES1 is a 
member of a family of transcriptional repressors (HES1-7; HEY1, HEY2, HEYL) that can 
be regulated by NOTCH, we investigated whether there was a significant correlation 
between cleaved NOTCH1 (NICD) status and the mRNA expression of the HES and 
HEY family members in HNSCC cell lines. All data was processed and analyzed by                
Dr. Jing Wang’s team in the Department of Bioinformatics at M.D. Anderson Cancer 
Center. Statisticians applied modified two-samples t-tests to the data sets to identify 
differentially expressed variables between the comparative groups. They also applied 
Spearman correlation and Pearson correlation analyses to the data sets to identify 
correlated variables between the comparative groups.  
We hypothesized that there would be a direct positive correlation between the 
mRNA expression of each of the HES and HEY family members and the cleaved 
NOTCH1 protein levels in the HNSCC cell lines. The scatterplot and barplot in Figure 6 
shows that HES5 is the only member of the HES and HEY family of transcriptional 
repressors to exhibit increased mRNA levels in HNSCC cell lines possessing high 
cleaved NOTCH1 protein [spearman.pval: 0.007; adj.p.val: 0.067]. The scatterplots in 
Figure 7 further confirm the findings.  
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Figure 6: HES5 mRNA expression significantly correlated with cleaved NOTCH1 
(NICD) protein levels in HNSCC. 
[A] Scatterplot comparing NOTCH1 activation status and HES/HEY mRNA expression. 
[B] Barplot comparing NOTCH1 activation status and HES/HEY mRNA expression. 
Measures of significance are color-coded, with coral bars constituting significant values 
and teal bars indicating insignificant values.  
(Analysis: Li Shen, PhD & Jing Wang, PhD, Department of Bioinformatics and 
Computational Biology)
A
B
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Figure 7: No significant correlation between HES/HEY mRNA expression and 
NOTCH1 activation status in HNSCC. 
[A] Scatterplots comparing HES family mRNA expression, with the exception of HES5, 
and cleaved NOTCH1 (NICD) protein levels in HNSCC cell lines. [B] Scatterplots 
comparing HEY family mRNA expression and cleaved NOTCH1 (NICD) protein levels in 
HNSCC cell lines. NOTCH1 mutant and NOTCH1 wild-type HNSCC cell lines are 
indicated with coral and teal dots, respectively. (Analysis: Li Shen, PhD & Jing Wang, 
PhD, Department of Bioinformatics and Computational Biology) 
 
 
A
B
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3.2 NOTCH1 wild-type HNSCC cell lines have diverse levels of NOTCH1 activation 
 
 HES1 is a well-established transcriptional target gene of the NOTCH1 pathway. 
In other words, active NOTCH1 signaling promotes the active transcription of HES1, 
leading to upregulated HES1 mRNA levels. Thus, HES1 mRNA levels were expected to 
be positively correlated with cleaved NOTCH1 protein levels in HNSCC cell lines. 
Because the results of the Spearman and Pearson correlation analyses were rather 
different from our hypothesis, we decided to examine the NOTCH1 activation of the 
NOTCH1 wild-type HNSCC cell lines. We collected lysate from 3 NOTCH1 wild-type 
HNSCC cell lines (FADU, PJ34, OSC19) after 24 hours and measured the basal protein 
levels of NOTCH1, NICD, HES1, and PTEN via western blot analysis.  
We expected that NOTCH1 wild-type HNSCC cell lines would display higher 
levels of NOTCH1 and NICD basal protein, suggesting increased NOTCH1 activation 
due to active NOTCH1 signaling, compared to mutant cell lines. Figure 8 reveals that the 
levels of cleaved NOTCH1 (NICD) protein vary across the NOTCH1 wild-type HNSCC 
cell lines (with overlapping levels observed in mutants), indicating that the NOTCH1 wild-
type HNSCC cell lines have diverse NOTCH1 activation. The diverse NOTCH1 and NICD 
protein levels also yielded diverse HES1 and PTEN protein levels across the cell lines. 
For instance, while higher protein levels of NOTCH1 and NICD correlated with higher 
protein levels of HES1 in some cell lines, lower protein levels of NOTCH1 and NICD 
correlated with lower protein levels of HES1 in other cell lines. These results may explain 
why the mRNA levels of HES1 did not correlate significantly with the protein levels of 
cleaved NOTCH1.  
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Figure 8: Diverse NOTCH1 activation in NOTCH1 wild-type HNSCC cell lines. 
[A] Western blot analysis of NOTCH1, NICD, HES1, and PTEN basal protein levels after 
24 hours in NOTCH1 wild-type HNSCC cell lines. [B] Bar graph comparing quantification 
of protein levels measured via western blot. NOTCH1 wild-type HNSCC cell lines are 
color-coded. FADU, PJ34, and OSC19 are indicated in red, purple, and blue, 
respectively.  
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3.3 Inhibition of NOTCH1 signaling does not significantly affect the PI3K-PTEN-
AKT/mTOR pathway in HNSCC 
 Preliminary experiments in our laboratory show that NOTCH1 mutant HNSCC cell 
lines are sensitive to dual PI3K/mTOR inhibitors. To investigate the mechanism of 
sensitivity in the cell lines, we explored the interaction between the NOTCH1 pathway 
and the PI3K-PTEN-AKT/mTOR pathway. We treated 3 NOTCH1 wild-type HNSCC cell 
lines (FADU, PJ34, and OSC19) at various time points (30 minutes, 2 hours, 4 hours, 8 
hours, and 24 hours) with OMP-52M51 at a concentration of 0.5ug/ml. We treated the 
control groups of the same cell lines with normal mouse IgG, an isotype control 
immunoglobulin, using the same concentration at the same time points. We then 
collected lysate and measured NOTCH1 pathway and PI3K-PTEN-AKT/mTOR pathway 
protein levels via western blot analysis. Experiments were repeated twice in each cell 
line for validity and reliability measures (n=2).  
OMP-52M51, also known as Brontictuzumab, is a first-in-class humanized IgG 
monoclonal antibody against NOTCH1. The antibody exerts its function by binding to the 
negative regulatory region (NRR) of the extracellular domain on the NOTCH1 receptor 
and changing its conformation. The conformational change prevents the receptor from 
binding to an adjacent ligand and ultimately blocks NOTCH1 signaling (Patnaik et al., 
2014). Figure 9 is a schematic of the functional activity of OMP-52M51 in vitro and in 
vivo. Although gamma secretase inhibitors are commonly used to inhibit NOTCH1 
signaling, we wanted to use a more specific inhibitor to prevent NICD cleavage. Using 
the active signaling of NOTCH1 in T-ALL as a model, we postulated that inhibiting 
NOTCH1 signaling in NOTCH1 wild-type HNSCC cell lines would lead to downregulated 
HES1 transcription and upregulated PTEN activity, thereby inactivating the 
PI3K/AKT/mTOR pathway. However, results of the experiment yielded a different 
 41  
outcome. Figure 10 shows that inhibiting the NOTCH1 pathway has no significant effect 
on HES1, PTEN, or the PI3K/AKT/mTOR pathway. While NOTCH1 signaling was 
blocked effectively in each cell line, there were no significant or consistent differences 
among the respective protein levels of the control and treated samples across the various 
time points.  
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Figure 9: Activity of OMP-52M51 in vitro and in vivo. 
Brontictuzumab, also known as OMP-52M51, is a first-in-class humanized IgG 
monoclonal antibody against NOTCH1. It binds to the negative regulatory region (NRR) 
of the NOTCH1 extracellular domain on the receptor and changes its conformation, 
preventing the receptor from binding to an adjacent ligand and blocking NOTCH1 
signaling. Permission obtained from Patnaik, A., LoRusso, P., Munster, P., Tolcher, 
A.W., Davis, S.L., Heymach, J., Ferrarotto, R., Xu, L., Kapoun, A.M., Faoro, L., Lewicki, 
J.A., Dupont, J., Eckhardt, S.G. (2014). EORTC-NCI-AACR Symposium. (Patnaik et al., 
2014).  
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Figure 10: Blocking NOTCH1 signaling has no significant effect on the PI3K-PTEN-
AKT/mTOR pathway. 
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTEN-
AKT/mTOR pathway protein levels after 0.5ug/ml OMP-52M51 treatment for 30 minutes, 
2 hours, 4 hours, 8 hours, and 24 hours in [A] FADU, [B] PJ34, and [C] OSC19. Pathway 
proteins are color-coded in line graphs.   
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3.4 Inhibition of NOTCH1 signaling has differential effects on HES1 and PTEN 
transcription in HNSCC  
 Previous studies show that inhibiting NOTCH1 signaling in NOTCH1 wild-type 
HNSCC cell lines has no significant or consistent effect on the PI3K-PTEN-AKT/mTOR 
pathway at the protein level. We investigated whether the same trend persisted at the 
mRNA level. Because results of the western blot analysis revealed that HES1 protein 
levels decreased the most after 8 hours of successful OMP-52M51 treatment, we 
repeated the treatment of FADU, PJ34, and OSC19 with 0.5ug/ml of OMP-52M51 for 8 
hours and isolated RNA. We then measured NOTCH1, HES1, and PTEN mRNA levels 
via qRT-PCR. Experiments were repeated twice in each cell line for validity and reliability 
measures (n=2).  
We hypothesized that inhibiting NOTCH1 signaling would downregulate HES1 
transcription, leading to decreased HES1 mRNA levels and increased PTEN mRNA 
levels. Nevertheless, we discovered that the results varied among the cell lines (Figure 
11). While HES1 mRNA levels decreased in FADU and PJ34 after blocking NOTCH1 
signaling, there was no significant effect on HES1 mRNA levels in OSC19 after 
treatment. Of note, there is a subtle decrease in HES1 protein in FADU and PJ34, as 
seen in Figure 10, at the same timepoint in which we observe decreased HES1 mRNA 
expression in the same cell lines. Moreover, blocking NOTCH1 signaling had no 
significant effect on PTEN transcription in FADU, PJ34, or OSC19. Taken together, the 
findings of the western blot and qRT-PCR analyses suggest that the well-established 
association between NOTCH1, HES1, and PTEN in T-ALL may be weak or nonexistent 
in HNSCC.  
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Figure 11: Blocking NOTCH1 signaling has differential effects on HES1 and PTEN 
transcription in HNSCC. 
Quantification of NOTCH1, HES1, and PTEN mRNA levels after qRT-PCR analysis of 
FADU, PJ34, and OSC19. Cell lines were treated with OMP-52M51 at a concentration 
of 0.5ug/ml for 8 hours. Control and treated samples are denoted in blue and red, 
respectively.  
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3.5 Knock down (KD) of NOTCH1 has no significant effect on the PI3K-PTEN-
AKT/mTOR pathway in HNSCC 
 To test our hypothesis using an independent method, we decided to employ a 
more genetic means of inhibiting NOTCH1 signaling. We treated the 3 NOTCH1 wild-
type HNSCC cell lines (FADU, PJ34, and OSC19) with 20nM siRNA targeting the 
NOTCH1 gene for 24 hours. NOTCH1 protein and mRNA have a half-life of 
approximately 1.5 hours, making 24 hours a suitable time point for silencing the NOTCH1 
gene (Nedjic and Aifantis, 2010). The control groups of the respective cell lines were 
treated with 20nM non-targeting siRNA for 24 hours. We then collected lysate and 
measured NOTCH1 pathway and PI3K-PTEN-AKT/mTOR pathway protein levels via 
western blot analysis. Experiments were repeated twice in each cell line for validity and 
reliability measures (n=2).  
We hypothesized that using siRNA to inhibit NOTCH1 signaling would lead to 
downregulated HES1 transcription and upregulated PTEN activity, thereby inactivating 
the PI3K/AKT/mTOR pathway in NOTCH1 wild-type HNSCC cell lines. However,          
Figure 12 shows that genetically blocking NOTCH1 signaling via siRNA has no significant 
effect on HES1, PTEN, or the PI3K/AKT/mTOR pathway. Although we successfully 
sustained approximately 70% knock down of the NOTCH1 gene, there were no 
differences among the NOTCH1 pathway and PI3K-PTEN-AKT/mTOR pathway proteins 
in the control and treated samples of each cell line. 
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Figure 12: Silencing NOTCH1 has no significant effect on the PI3K-PTEN-
AKT/mTOR pathway. 
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTEN-
AKT/mTOR pathway protein levels after 20nM siRNA treatment for 24 hours in [A] FADU, 
[B] PJ34, and [C] OSC19. Control and treated samples are denoted in blue and red, 
respectively.  
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3.6 Knockout (KO) of NOTCH1 leads to differential effects on the PI3K-PTEN-
AKT/mTOR pathway   
 Using siRNA to silence the NOTCH1 gene successfully inhibited NOTCH1 
signaling, but did not have a significant effect on HES1 or the PI3K-PTEN-AKT/mTOR 
pathway. We decided to use a more specific genetic approach to prevent NOTCH1 
signaling. We received FADU and PJ34 Crispr/Cas9-generated NOTCH1 KO cell lines 
from Dr. Mitchell Frederick’s laboratory. Because both alleles of NOTCH1 are stably 
deleted from both cell lines, we resolved this method of blocking NOTCH1 signaling to 
be the most efficient method of inhibition. We cultured the respective cell lines for 24 
hours, collected lysate, and measured the NOTCH1 pathway and PI3K-PTEN-
AKT/mTOR pathway proteins via western blot analysis. Cells in the control group were 
transfected with an empty vector. Experiments were repeated twice in each cell line for 
validity and reliability measures (n=2). 
We proposed that genetically deleting both alleles of NOTCH1 would effectively 
prevent NOTCH1 signaling, leading to markedly increased PTEN activity and the 
subsequent inactivation of the PI3K-PTEN-AKT/mTOR pathway. Strikingly, the results 
were cell-line-specific. While both Crispr/Cas9-generated NOTCH1 KO cell lines 
successfully inhibited NOTCH1 signaling, as confirmed by the absence of NOTCH1 and 
NICD protein, the effect on the PI3K-PTEN-AKT/mTOR pathway was different in each 
cell line. Although the NOTCH1 KO treatment led to inactivation of the PI3K-PTEN-
AKT/mTOR pathway in FADU, it led to activation of the pathway in PJ34 (Figure 13). The 
results are irrespective of the HES1 and PTEN protein levels, which were not affected 
by the NOTCH1 KO treatment, in each cell line. The data further confirms the observation 
that the NOTCH1-HES1-PTEN interaction in T-ALL may be weak or nonexistent in 
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HNSCC. The data also suggests that if there is a link between the NOTCH1 and PI3K-
PTEN-AKT/mTOR pathways in HNSCC, it may vary across the cell lines.  
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Figure 13: NOTCH1-/- leads to differential effects on the PI3K-PTEN-AKT/mTOR 
pathway.   
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTEN-
AKT/mTOR pathway protein levels in [A] FADU and [B] PJ34 Crispr/Cas9-generated 
NOTCH1 KO cell lines. Parental, control, and NOTCH1 KO samples are indicated by 
blue, green, and red, respectively.   
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3.7 Knockout (KO) of NOTCH1 leads to differential effects on HES1 and PTEN 
transcription in HNSCC 
 The Crispr/Cas9-generated deletion of both alleles of NOTCH1 proved to be the 
most effective method of inhibiting NOTCH1 signaling. As a result, we sought to explore 
the effect of this method of inhibition on the transcription of HES1 and PTEN in HNSCC. 
We cultured FADU and PJ34 Crispr/Cas9-generated NOTCH1 KO cell lines for 24 hours, 
isolated RNA, and measured NOTCH1, HES1, and PTEN mRNA levels via qRT-PCR. 
Cells in the control group were transfected with an empty vector. Experiments were 
repeated twice in each cell line for validity and reliability measures (n=2). 
 Based on the well-known NOTCH1-HES-PTEN association in T-ALL, we 
postulated that the Crispr/Cas9-mediated inhibition of NOTCH1 signaling would 
significantly decrease HES1 transcription and greatly increase PTEN transcription. The 
findings displayed in Figure 14 show that Crispr/Cas9-mediated inhibition of NOTCH1 
signaling significantly downregulates HES1 transcription but has no significant effect on 
PTEN transcription in both cell lines. The data is promising because it supports the 
premise of the central hypothesis, which holds that HES1 transcription is regulated by 
the NOTCH1 pathway. Additionally, the results of the western blot and qRT-PCR 
analyses in the Crispr/Cas9-generated NOTCH1 KO cell lines are the only evidence that 
an interaction between the NOTCH1 pathway and the PI3K-PTEN-AKTmTOR pathway 
exists in HNSCC. Although the mediators of communication between the pathways in 
HNSCC may differ from those in T-ALL, the data suggests that an interaction between 
the pathways is present in HNSCC. 
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Figure 14: NOTCH1-/- has differential effects on HES1 and PTEN transcription in 
HNSCC. 
Quantification of NOTCH1, HES1, and PTEN mRNA levels after qRT-PCR analysis of 
[A] FADU and [B] PJ34 Crispr/Cas9-generated NOTCH1 KO cell lines. Parental and 
NOTCH1 KO samples are indicated by blue and red, respectively.  
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3.8 Restoration of NOTCH1 signaling has no significant effect on the PI3K-PTEN-
AKT/mTOR pathway in HNSCC 
 Because the results of the western blot and qRT-PCR analyses in the 
Crispr/Cas9-generated NOTCH1 KO cell lines were in accordance with our central 
hypothesis, we sought to validate the findings by restoring active NOTCH1 signaling in 
the NOTCH1 KO cell lines. Dr. Mitchell Frederick’s laboratory also developed FADU and 
PJ34 Crispr/Cas9-generated NOTCH1 KO cell lines that expressed a doxycycline-
inducible Notch1 intracellular domain (NICD) system. Simply put, the inducible NICD 
system allowed us to restore active NOTCH1 signaling in the NOTCH1 KO cell lines, 
which are entirely deficient of any NOTCH1 signaling capabilities. We treated both cell 
lines with 100ng/ml of doxycycline for 24 hours. We then collected lysate and measured 
NOTCH1 pathway and PI3K-PTEN-AKT/mTOR pathway protein levels via western blot 
analysis. Experiments were repeated twice in each cell line for validity and reliability 
measures (n=2).  
 We expected that restoring active NOTCH1 signaling in the NOTCH1 KO cell lines 
would yield an effect on the PI3K-PTEN-AKT/mTOR pathway that was the opposite of 
what was exhibited in the Crispr/Cas9-mediated inhibition of NOTCH1 signaling. 
Restoring NOTCH1 signaling would upregulate HES1 transcription and downregulate 
PTEN activity, resulting in the hyper-activation of the PI3K/AKT/mTOR pathway. 
However, restoring NOTCH1 signaling had no significant effect on HES1 or the PI3K-
PTEN-AKT/mTOR pathway in either cell line (Figure 15). There were no consistent or 
significant differences among the pathway proteins in the control and treated samples of 
each of the cell lines. The data offers a strong rationale for moving further along the 
NOTCH1 pathway and focusing on the manipulation of HES1 to investigate the 
interaction between the NOTCH1 and the PI3K-PTEN-AKT/mTOR pathways. 
 62  
   
P
ar
e
n
t
P
ar
e
n
t
C
o
n
tr
o
l	(
e
m
p
ty
	v
e
ct
o
r)
FADU
C
o
n
tr
o
l	(
e
m
p
ty
	v
e
ct
o
r)
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)	
+	
iN
IC
D
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)	
+	
iN
IC
D
- + - + - + - +Dox	(100ng)
NICD
Hes1
PTEN
Notch2
Notch1
4EBP1
β-actin
pS6	(S240/244)
p4EBP1	(S65)
pAKT	(S473)
pS6	(S235/236)
P
ar
e
n
t
P
ar
e
n
t
C
o
n
tr
o
l	(
e
m
p
ty
	v
e
ct
o
r)
FADU
C
o
n
tr
o
l	(
e
m
p
ty
	v
e
ct
o
r)
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)	
+	
iN
IC
D
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)	
+	
iN
IC
D
- + - + - + - + Dox	(100ng)
AKT
S6
Notch3
Notch4
pPTEN (Ser380,	Thr382/383)
A
P T E N p AK T (S 4 7 3 ) /AK T p S 6 (S 2 3 5 /2 3 6 ) /S 6 p S 6 (S 2 4 0 /2 4 4 ) /S 6 p 4 E B P 1 (S 6 5 ) /4 E B P 1
0 .0
0 .5
1 .0
1 .5
2 .0
P I3 K  P A T H W A Y
p
r
o
te
in
 l
e
v
e
l 
(f
o
ld
 c
h
a
n
g
e
)
P a re n t
C o n tro l
N O T C H 1  K O
N O T C H 1  K O  +  iN IC D
N O T C H 1  N O T C H 2 N O T C H 3 N O T C H 4 N IC D H E S 1
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
1 0
1 5
2 0
2 5
3 0
3 5
N O T C H 1  P A T H W A Y
p
r
o
te
in
 l
e
v
e
l 
(f
o
ld
 c
h
a
n
g
e
)
P a re n t
C o n tro l
N O T C H 1  K O
N O T C H 1  K O  +  iN IC D
 63  
          
 
 
 
 
   
Dox	(100ng)
NICD
Hes1
PTEN
Notch2
Notch1
Notch3
Notch4
pPTEN (Ser380,	Thr382/383)
P
ar
e
n
t
P
ar
e
n
t
PJ34
N
O
TC
H
1
-/
-
N
O
TC
H
1
-/
-
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)	
+	
iN
IC
D
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)	
+	
iN
IC
D
- + - + - +
4EBP1
β-actin
pS6	(S240/244)
p4EBP1	(S65)
pAKT	(S473)
pS6	(S235/236)
AKT
S6
P
ar
e
n
t
P
ar
e
n
t
PJ34
N
O
TC
H
1
-/
-
N
O
TC
H
1
-/
-
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)	
+	
iN
IC
D
N
O
TC
H
1
-/
-
(C
lo
n
e
	2
)	
+	
iN
IC
D
- + - + - +
B
N O T C H 1  N O T C H 2 N O T C H 3 N O T C H 4 N IC D H E S 1
0
1
2
3
4
N O T C H 1  P A T H W A Y
p
ro
te
in
 l
e
v
e
l 
(f
o
ld
 c
h
a
n
g
e
)
P a re n t
N O T C H 1  K O
N O T C H 1  K O  +  iN IC D
P T E N p AK T (S 4 7 3 ) /AK T p S 6 (S 2 3 5 /2 3 6 ) /S 6 p S 6 (S 2 4 0 /2 4 4 ) /S 6 p 4 E B P 1 (S 6 5 ) /4 E B P 1
0 .0
0 .5
1 .0
1 .5
2 .0
P I3 K  P A T H W A Y
p
r
o
te
in
 l
e
v
e
l 
(f
o
ld
 c
h
a
n
g
e
)
P a re n t
N O T C H 1  K O
N O T C H 1  K O  +  iN IC D
 64  
Figure 15: Restoring NOTCH1 signaling has no significant effect on the PI3K-
PTEN-AKT/mTOR pathway in HNSCC. 
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTEN-
AKT/mTOR pathway protein levels in [A] FADU and [B] PJ34 Crispr/Cas9-generated 
NOTCH1 KO cell lines transfected with the inducible NICD vector. Parental, control, 
NOTCH1 KO, and NOTCH1 KO + iNICD samples are indicated by blue, green, red, and 
purple, respectively.   
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3.9 Knock down (KD) of HES1 has no significant effect on the PI3K-PTEN-
AKT/mTOR pathway in HNSCC 
 According to the outcomes of previous experiments, we have concluded that 
manipulating the NOTCH1 pathway does not have a significant or consistent effect on 
the PI3K-PTEN-AKT/mTOR pathway in HNSCC. However, manipulating the pathway 
has a minimal effect on HES1 protein levels in HNSCC. We postulate that manipulating 
HES1 may affect PTEN transcription because HES1 is a more direct regulator of PTEN 
and ultimately PI3K/AKT/mTOR pathway activity. We treated the 3 NOTCH1 wild-type 
HNSCC cell lines (FADU, PJ34, and OSC19) with 20nM siRNA targeting the HES1 gene 
for 24 hours. HES1 protein and mRNA have a half-life of approximately 20 minutes, 
making 24 hours a suitable time point for silencing the HES1 gene (Kobayashi et al., 
2015). The control groups of the respective cell lines were treated with 20nM non-
targeting siRNA for 24 hours. We then collected lysate and measured NOTCH1 pathway 
and PI3K-PTEN-AKT/mTOR pathway protein levels via western blot analysis. 
Experiments were repeated twice in each cell line for validity and reliability measures 
(n=2). 
 Figure 16 reveals that silencing the HES1 gene has no significant effect on PTEN 
or the PI3K/AKT/mTOR pathway in either of the cell lines. Taken together with the 
experiments involved in manipulating NOTCH1 signaling, the data supports the 
observation that the NOTCH1 pathway does not affect the PI3K-PTEN-AKT/mTOR 
pathway in HNSCC. Given the unestablished NOTCH-HES1-PTEN association in 
HNSCC, we should explore other potential mediators of communication between the 
NOTCH1 pathway and the PI3K-PTEN-AKT/mTOR pathway in HNSCC (i.e. PTEN or 
AKT). 
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Figure 16: Silencing HES1 has no significant effect on the PI3K-PTEN-AKT/mTOR 
pathway. 
Western blot analysis and quantification of NOTCH1 pathway and PI3K-PTEN-
AKT/mTOR pathway protein levels after 20nM siRNA treatment for 24 hours in [A] FADU, 
[B] PJ34, and [C] OSC19. Control and treated samples are denoted in blue and red, 
respectively.  
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CHAPTER 4:  
DISCUSSION & FUTURE DIRECTIONS 
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4.1 Discussion 
 While the oncogenic role of NOTCH1 is well-established in T-ALL, the tumor 
suppressive role of NOTCH1 in HNSCC is poorly understood. Preliminary studies in our 
laboratory report that NOTCH1 mutant HNSCC cell lines are sensitive to dual 
PI3K/mTOR inhibitors, suggesting a potential interaction between the NOTCH1 and 
PI3K-PTEN-AKT/mTOR pathways in vivo. In T-ALL, the crosstalk between both 
pathways has been heavily studied and is distinctively characterized in the literature. In 
HNSCC, on the other hand, the interaction between both pathways is largely unknown 
and remains the focus of most prominent research in the field. Although the findings of 
many of the experiments in this research consist of negative data, we have been able to 
formulate rather insightful conclusions regarding the interaction between the NOTCH1 
and PI3K-PTEN-AKT/mTOR pathways in HNSCC.  
We employed three methods of inhibition to block NOTCH1 signaling in NOTCH1 
wild-type HNSCC cell lines, with each successive method being more specific in its 
targeting potential than its predecessor. Using OMP-52M51 to block NOTCH1 signaling 
had no significant effect on HES1 or the PI3K-PTEN-AKT/mTOR pathway at the protein 
level. Additionally, silencing the NOTCH1 gene to block NOTCH1 signaling had no 
significant effect on HES1 or the PI3K-PTEN-AKT/mTOR pathway at the protein level. 
The findings of these experiments suggest the nonexistence of any type of interaction 
between the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways in HNSCC.  
 On the other hand, employing a more specific genetic method to prevent NOTCH1 
signaling yielded more promising results. The Crispr/Cas9-mediated inhibition of 
NOTCH1 signaling led to downregulated PI3K/AKT/mTOR activity in FADU and 
upregulated PI3K/AKT/mTOR activity in PJ34. The findings restore our confidence in the 
initial observation that a possible interaction exists between the NOTCH1 and PI3K-
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PTEN-AKT/mTOR pathways in HNSCC. Nevertheless, the cell-line-specific findings 
show that the pathways may be regulated differently across the cell lines. The findings 
further suggest that the active domains of the NOTCH1 receptor must be completely 
removed from the cell to effectively inhibit its signaling and observe any effects that 
pathway inhibition may have on other pathways in the cell. Because the treatment had 
no significant effect on the HES1 and PTEN protein levels of both cell lines, we can infer 
that the potential crosstalk between both pathways is not mediated by either HES1 or 
PTEN.   
 Restoring NOTCH1 signaling in NOTCH1 wild-type HNSCC cell lines had no 
significant effect on HES1 or the PI3K-PTEN-AKT/mTOR pathway at the protein level, 
imparting a fundamental indication that the link between both pathways may be a rather 
weak link. However, qRT-PCR analysis following each method of inhibiting NOTCH1 
signaling revealed that HES1 mRNA levels were significantly reduced after blocking 
NOTCH1 signaling, but there was no effect on the PTEN mRNA levels. The findings 
confirm that the NOTCH1-HES1 association present in T-ALL is also present in HNSCC. 
Inactivating NOTCH1 signaling inhibits HES1 transcription, resulting in significantly 
decreased HES1 mRNA levels. The results also suggest that the well-established 
interaction between HES1 and PTEN in T-ALL is not present in HNSCC. Additionally, 
silencing HES1 had no significant effect on PTEN or the PI3K/AKT/mTOR pathway at 
the protein level, providing sufficient evidence that the link between HES1 and PTEN 
does not exist in HNSCC. Taken together, the results of the experiments in this research 
support the observation that an interaction does not exist between the NOTCH1 pathway 
and the PI3K-PTEN-AKT/mTOR in HNSCC. 
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4.2 Future Directions 
 The findings of this project provide valuable insight into understanding whether 
the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways communicate in HNSCC. The data 
also imparts fundamental objectives for directing experimental efforts to identify potential 
mediators of communication between both pathways. Establishing a distinct relationship 
between NOTCH1, HES1 and PTEN in HNSCC cell lines is crucial to understanding how 
the NOTCH1 and PI3K-PTEN-AKT/mTOR pathways communicate in HNSCC. 
Unfortunately, the experimental efforts executed in this project did not succeed in 
identifying the mechanism of crosstalk between both pathways.  
Employing more specific genetic methods to manipulate target proteins will enable 
us to study the effects of the respective treatments on pathway interactions. For instance, 
utilizing Crispr/Cas9 methodologies to genetically delete both alleles of HES1 from the 
cells may enable us to identify an association between HES1 and PTEN in HNSCC. We 
will also consider the possibility of bidirectional crosstalk between the pathways in 
HNSCC. To test our hypothesis, we will employ chemical and genetic methodologies to 
manipulate each component of the PI3K-PTEN-AKT/mTOR pathway and measure the 
effect the treatment has on the NOTCH1 pathway. Additionally, utilizing high throughput, 
quantitative, functional proteomic and genomic technologies, such as reverse phase 
protein array (RPPA) and RNA sequencing, will aid us in narrowing our search for more 
specific mediators of communication between both pathways. Elucidating the potential 
mechanisms of communication between the NOTCH1 and the PI3K-PTEN-AKT/mTOR 
pathways presents both pathways as fundamental targeting agents for improving many 
HNSCC targeted therapies. 
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